Testing MIB-626 for safety in adults with Down syndrome to address Alzheimer's disease
Tests the safety of MIB-626 tablets in adults with Down syndrome.
Key facts
- Who runs it
- Brigham and Women's Hospital
- Where
- Boston, United StatesSee the 2 sites
- Trial code
- Registry title
- NAD Augmentation to Prevent or Reverse Alzheimer's Disease in People With Down Syndrome
- Status
- Not yet recruiting
- Phase
- Phase 1
- People taking part
- 24 people, planned
- Started
- 31 Aug 2026
- Expected to end
- 31 May 2028
- Type of study
- Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- MIB-626
- Placebo
- Record updated
- 19 August 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with Down syndrome who are medically stable. It tests the safety of a daily tablet, MIB-626, against a placebo for 28 days.
- Age
- 18 years or older
- Sex
- All sexes can join. Women must not be pregnant and must not plan to become pregnant in the next 6 months.
- Disease stage
- Down syndrome with full trisomy of chromosome 21 or a complete unbalanced translocation of chromosome 21, confirmed by karyotype analysis or clinical documentation.
- Earlier treatment
- People must not have joined a trial of a drug or biologic in the past 3 months or 5 half-lives, whichever is shorter.
Main reasons for not taking part
- Kidney problems: fasting morning UACR above 5,000 mg/g creatinine, or eGFR below 30 mL/min/1.73 m2
- Liver tests (AST or ALT) more than 3 times the upper limit of normal
- A major heart or blood vessel event in the past 3 months
- A serious mental illness or behavior problems that could get in the way of the study
- Cannot walk on their own
This trial only enrols participants with Down syndrome. The registry sentence this rests on: A diagnosis of full trisomy for chromosome 21 or complete unbalanced translocation of chromosome 21, confirmed by karyotype analysis or clinical documentation.
The registry criteria, word for word
Show all 15 criteriaShow less
Who can take part
- A diagnosis of full trisomy for chromosome 21 or complete unbalanced translocation of chromosome 21, confirmed by karyotype analysis or clinical documentation
- 18 years or older
- Participant has a caregiver/ informant who has direct contact with the participant >10 hours/ week and who can provide information about participant's health
- Participant or Legal Authorized Representative is able to understand and willing to provide written informed consent and capable of completing study assessments
- In addition, female participants must Not be pregnant and not planning to become pregnant over the next 6 months
Who cannot take part
- Current alcohol or substance use disorder or dependence (DSM 5 criteria)
- Major depressive disorder, bipolar disorder, schizophrenia, or current psychotic symptoms or behavioral problems that could interfere with study procedures
- An acute illness, including COVID-19, requiring hospitalization within the past 3 months or any acute illness, including COVID-19, within the past month
- Has a history of anaphylaxis from vitamin B3 derivatives
- Fasting morning UACR > 5,000 mg/ g creatinine
- Other laboratory abnormalities:; Has AST or ALT > 3 times the upper limit of normal; eGFR < 30 mL/ min / 1.73 m2; Hematocrit < 0.34 or > 0.50 L/L
- A major adverse cardiovascular event in preceding 3 months
- Participation in an investigational trial to evaluate pharmaceuticals or biologics within the past 3 months or 5 half-lives, whichever is shorter
- BMI > 42.5 kg/ m2
- Non-ambulatory
Where in United States
- Brigham and Women's HospitalBoston, United StatesContact: Nancy Latham, PhDNot yet recruiting
- Massachusetts General HospitalBoston, United StatesContact: Brian Skotko, MD, MPPNot yet recruiting
About the trial
What the trial wants to find out
The aim of the study is to determine the safety and tolerability of different increasing doses of MIB-626 (a microcrystalline form of β nicotinamide mononucleotide; NMN) given daily for 28 consecutive days to adults with Down syndrome (DS). The study will also explore how the drug moves through the body over time (pharmacokinetics or PK) and how the drug affects the body in different ways (pharmacodynamics or PD). The study participants will be monitored for adverse events and measurements to detect safety events will take place including laboratory tests of blood counts, chemistries and coagulation profile, and electrocardiogram (ECG). The trial will enroll a total of 24 adults with DS who are 18 years or older and are medically stable. People enrolled in the study will be randomly assigned to receive either the active intervention (MIB-626) tablets, or placebo tablets for 28 days. Study participants will be followed for an additional 28 days (total 56 days of follow-up). This study will also explore the effect of MIB-626 on different measures associated with aging and risk of Alzheimer's Disease (AD).
The 2 groups in the trial
- Safety and pharmacokinetic ascending dose intervention groupTreatment being tested
MIB-626 tablets will be provided at dose strength of 500mg. Three doses will be studied in ascending order: 500 mg (one tablet) once daily; 1000 mg (two 500 mg tablets once daily) or 1000 mg (two 500 mg tablets) twice daily.
Treatment: MIB-626
- Placebo tabletsPlacebo, for comparison
Matching placebo tablets (number and frequency of tablets will match the active intervention group at each of the three doses)
Treatment: Placebo
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Nicotinamide Adenine Dinucleotide Augmentation to Prevent or Reverse the Progression of Alzheimer's Disease in People With Down Syndrome
- Plain-language title
- Testing MIB-626 for safety in adults with Down syndrome to address Alzheimer's diseaseGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 19 August 2026